A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an intervention integrating contingency management (financial incentives) to enhance hepatitis C treatment uptake following dried blood spot hepatitis C RNA testing among people with recent injecting drug use attending needle and syringe programs: the AMPLIFY study
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Enrollment
400
Incentive payment to enhance HCV treatment uptake among people with recent injecting drug use attending needle and syringe programs.
The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing
Data will be presented in percentages and mean (SD) or median values (interquartile range), as appropriate. Chi square test or Fisher's exact test will be utilised, as appropriate, to examine between group differences.
Time frame: 6 months
Feasibility of recruitment through a peer-based referral incentivization scheme
Recruitment numbers
Time frame: 6 months
Time to HCV treatment initiation
Time frame: 6 months
Time to HCV treatment completion
Time frame: 6 months
Time to visit to confirm viral cure (e.g. sustained virological response, SVR12)
Time frame: 6 months
Participant perceptions and acceptability of being involved in a contingency management study will be assessed by study questionnaire
Time frame: 6 months
Feasibility of a contingency management intervention to enhance hepatitis C treatment uptake
Proportion of participants who enrolled in the study and where assigned treatment who commenced treatment.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.